

**Zydus Cadila receives USFDA approval for Losartan Potassium tablets  
and Losartan Potassium + Hydrochlorothiazide tablets**

*Launches products on the very same day*

Ahmedabad, October 07, 2010

Zydus Cadila has received an approval from the USFDA to market Losartan Potassium tablets (25mg, 50mg and 100mg) and Losartan Potassium + Hydrochlorothiazide tablets (50/12.5mg and 100/25mg) in the US market. Gaining a significant advantage, Zydus Pharmaceuticals (USA) Inc., launched both products on the very same day after receiving approvals from the USFDA.

The drugs fall in the anti-hypertensive segment and are used for treating high blood pressure. The sales of Losartan Potassium tablets in the US market is estimated at USD 1.3 bn and that of Losartan Potassium + Hydrochlorothiazide tablets is estimated at USD 944 mn in 2010 as per NDC Health.

The group has 56 approvals and has so far filed 113 ANDAs since the commencement of filing process in FY 2003-04.

\*\*\*